“On the other hand there will be cases where there are vital national interests, in this case large-scale investment of R&D. The question is how you protect it. What the government did then [during Pfizer's proposed takeover] was to engage in negotiations to seek assurances. Where we now have to strengthen that is to make sure that with any commitments made there is no wriggle room.”